As well as providing a potential route to targeting MYC driven tumours, CDK1 inhibition has also been proposed as a route to causing chemosensitivity, enhancing the effects of PARP inhibitors [46] as well as PI3-kinase inhibitors [47]. Here, CDK1 is linked to neoplasm.